Neoadjuvant treatment with disitamab vedotin monotherapy in patients with HER2-overexpressing muscle invasive bladder cancer (MIBC): An open-label, single-arm, phase II study.

Authors: Houfeng Huang, Xuebin Zhang, Yi Xie, Yi Zhao, Yushi Zhang, Xinrong Fan

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e16584

Source: Full article

---

Abstract

e16584